The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer - Takeaways - MDSpire

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

  • By

  • Veera Nurmela

  • Anni Juntunen

  • Satu Tiainen

  • Janne Martikainen

  • Sanna Pasonen-Seppänen

  • Aino Rönkä

  • June 23, 2026

  • 0 min

Share

  • 1

    61% of patients with immune-related adverse events (irAE) experienced chronic toxicity lasting over 12 weeks.

  • 2

    43% of irAEs required corticosteroid treatment, with 49% of these patients undergoing prolonged therapy exceeding 12 weeks.

  • 3

    Management of irAEs necessitated an average of 5.3 contacts with a medical oncologist per irAE.

  • 4

    Chronic irAEs often involve irreversible organ damage and may require complex management strategies.

  • 5

    The study analyzed the burden of chronicity and challenges of corticosteroid therapy in patients treated with immune checkpoint inhibitors.

Original Source(s)

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

  • by Veera Nurmela, Anni Juntunen, Satu Tiainen, Janne Martikainen, Sanna Pasonen-Seppänen, Aino Rönkä

  • June 23, 2026

Related Content

Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway